Advertisement

Nuclear Medicine and Molecular Imaging

, Volume 52, Issue 5, pp 394–397 | Cite as

Langerhans’ Cell Histiocytosis Masquerading as Metastatic Papillary Thyroid Cancer on F-18 FDG PET/CT: Diagnostic Dilemma Solved by PET/CT-Guided Biopsy

  • Dharmender Malik
  • Rajender Kumar
  • Bhagwant Rai Mittal
  • Gaurav Parkash
  • Amanjit Bal
  • Anish Bhattacharya
Interesting Image

Abstract

We present a case of papillary thyroid cancer (post-thyroidectomy status) on regular treatment with suppressive Levothyroxine therapy. On follow-up at 6 months after radioactive iodine ablation for remnant thyroid tissue, her thyroglobulin, and anti-thyroglobulin levels were 0.06 ng/ml and 670 IU/ml, respectively. Low-dose whole-body I-131 scan was negative. To look for the cause of isolated increased anti-thyroglobulin level, a whole-body 18F-FDG PET/CT was done which revealed multiple FDG-avid lytic skeletal lesions suggestive of metastases. For confirmation of diagnosis, 18F-FDG PET/CT-guided metabolic biopsy was done, which revealed Langerhans’ cell histiocytosis on histopathological examination.

Keywords

Papillary thyroid cancer Langerhans’ cell histiocytosis Anti-thyroglobulin level 18F-FDG PET/CT PET/CT-guided biopsy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dharmender Malik, Rajender Kumar Basher, Bhagwant Rai Mittal, Gaurav Parkash, Amanjit Bal, and Anish Bhattacharya declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.

Informed Consent

The institutional review board of our institute approved this retrospective study, and the requirement to obtain informed consent was waived.

References

  1. 1.
    Qiu ZL, Wei WJ, Shen CT, Song HJ, Zhang XY, Sun ZK, et al. Diagnostic performance of 18F-FDG PET/CT in papillary thyroid carcinoma with negative 131I-WBS at first post-ablation, negative Tg and progressively increased TgAb level. Sci Rep. 2017;7:2849.  https://doi.org/10.1038/s41598-017-03001-7.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab. 2008;22:955–69.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Mihailovic J, Stefanovic L, Malesevic M. Differentiated thyroid carcinoma with distant metastases: the probability of survival and its predicting factors. Cancer Biother Radiopharm. 2007;22:250–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery. 2008;143:35–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Lee J, Soh E-Y. Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis. Ann Surge. 2010;251:114–9.CrossRefGoogle Scholar
  7. 7.
    Showalter TN, Siegel BA, Moley JF, Baranski TJ, Grigsby PW. Prognostic factors in patients with well-differentiated thyroid cancer presenting with pulmonary metastasis. Cancer Biother Radiopharm. 2008;23:655–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Borschitz T, Eichhorn W, Fortner C, Hansen T, Schad A, Schadmand-Fischer, et al. Diagnosis and treatment of pancreatic metastases of a papillary thyroid carcinoma. Thyroid. 2010;20:93–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Badalian-Very G, Vergilio J-A, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919–23.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lian C, Lu Y, Shen S. Langerhans cell histiocytosis in adults: a case report and review of the literature. Oncotarget. 2016;7:18678–83.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Patten DK, Wani Z, Tolley N. Solitary Langerhans histiocytosis of the thyroid gland: a case report and literature review. Head Neck Pathol. 2012;6:279–89.CrossRefPubMedGoogle Scholar
  13. 13.
    Pusztaszeri MP, Sauder KJ, Cibas ES, Faquin W. C. Fine-needle aspiration of primary Langerhans cell histiocytosis of the thyroid gland, a potential mimic of papillary thyroid carcinoma. Acta Cytol. 2013;57:406–12.CrossRefPubMedGoogle Scholar
  14. 14.
    Yaˇgcı B, Kandemir N, Yazıcı N, Yalçın B, Varan A, Akyü C, et al. Thyroid involvement in Langerhans cell histiocytosis: a report of two cases and review of the literature. Eur J Pediatr. 2007;166:901–4.CrossRefGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2018

Authors and Affiliations

  • Dharmender Malik
    • 1
  • Rajender Kumar
    • 1
  • Bhagwant Rai Mittal
    • 1
  • Gaurav Parkash
    • 2
  • Amanjit Bal
    • 3
  • Anish Bhattacharya
    • 1
  1. 1.Department of Nuclear MedicinePostgraduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia
  2. 2.Department of Internal MedicinePostgraduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia
  3. 3.Department of PathologyPostgraduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia

Personalised recommendations